Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.72 |
| ▸ | CCR3 | P51677 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20858759 | 0.90 | GBA1 (0.66) | GBA1CCR3SLC6A4KDM1AMAOB | |
| SCHEMBL8101593 | 0.87 | GBA1 (0.82) | GBA1CCR3SLC6A4CARM1PRMT6 | |
| SCHEMBL87612 | 0.85 | GBA1 (1.00) | GBA1CCR3SLC6A4CARM1PRMT6 | |
| SCHEMBL14256044 | 0.83 | GBA1 (0.50) | GBA1CCR3KDM1AMAOB | |
| Hydrochloric Acid SCHEMBL4935892 | 0.83 | GBA1 (0.96) | GBA1CCR3SLC6A4CARM1PRMT6 | |
| Bromide SCHEMBL10728442 | 0.83 | GBA1 (0.96) | GBA1CCR3SLC6A4CARM1PRMT6 | |
| Ethylamine SCHEMBL3323945 | 0.80 | GBA1 (0.82) | GBA1CCR3SLC6A4CARM1PRMT6 | |
| Formaldehyde SCHEMBL28466516 | 0.80 | GBA1 (0.89) | GBA1CCR3SLC6A4CARM1PRMT6 | |
| SCHEMBL1428015 | 0.78 | GBA1 (0.85) | GBA1CCR3SLC6A4 | |
| SCHEMBL8891663 | 0.78 | GBA1 (0.85) | GBA1CCR3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317648-A1 | THERAPEUTIC COMPOUNDS | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2010-12-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317648-A1 | THERAPEUTIC COMPOUNDS | MAOB, MAOA, HTR1B | GBA1 472/4885CCR3 4684/4885SLC6A4 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.